This activity has been designed to meet the educational needs of nephrologists, hepatologists, gastroenterologists, hospitalists, and pharmacists involved in the care of patients with hepatorenal syndrome (HRS).
The purpose of this satellite symposium will be to provide education on the latest emerging data for the management and treatment of HRS. The joint providership anticipates reaching 200 participants during the in-person symposium. To accommodate healthcare professionals who prefer distance learning, an additional 75 participants will be reached via a webcast livestream of the symposium. This approach will still ensure the initiative's goal of educating on the local level and providing participants with the opportunity of live interactions with healthcare experts.
After completing this activity, the participant should be better able to:
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and the Chronic Liver Disease Foundation (CLDF). MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medical Education Resources designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Relevant Financial Relationships
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are mitigated by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
Americans with Disabilities Act:
The event staff will be glad to assist you with any special needs (i.e., physical, dietary). Please contact us prior to the event at 1-888-565-5321.
This activity is jointly provided by Medical Education Resources and the Chronic Liver Disease Foundation.
Supported by an educational grant from Mallinckrodt Pharmaceuticals.
6:00 PM PT
6:10 PM PT
6:20 PM PT
6:30 PM PT
6:40 PM PT
6:50 PM PT
7:00 PM PT
Steven L. Flamm, MD, is a Professor of Medicine, Clinical Director of Network Development for Liver Transplantation, and Director of Clinical Research in the Section of Hepatology at Rush University Medical Center in Chicago, Illinois. He formerly served as the Chief of the Hepatology Program and Medical Director of Liver Transplantation at the Feinberg School of Medicine. Dr. Flamm received his MD degree from the University of Pennsylvania School of Medicine. He completed both a clinical fellowship in gastroenterology and a research fellowship in gastroenterology and hepatology at Beth Israel Hospital, Harvard Medical School. He then received further specialized training, completing a clinical fellowship in hepatology and liver transplantation at the Deaconess Hospital, Harvard Medical School. Dr. Flamm is a member of the American Gastroenterological Association (AGA) and is a fellow in the American Association for the Study of Liver Diseases (AASLD) and American College of Gastroenterology (ACG). He has served as the Region 7 Representative to the UNOS Liver and Intestine Committee and on the Publication and Practice Guidelines Committee of the AASLD. Further, he is currently a Trustee of the AASLD Foundation and Chair of the AASLD Development Committee. He is currently a member of the Global Outreach Committee and the Chair of the Industry Advancement Committee.
Locally, Dr. Flamm was the American Liver Foundation Annual Honoree in 2015 and has been Chicago Top Doctor since 2019. Dr. Flamm has published widely in the field of hepatic diseases and has spoken both nationally and internationally on many other liver-related topics, including viral hepatitis, autoimmune hepatitis, hepatic encephalopathy, and liver transplantation. Dr. Flamm has also been a guest editor for five separate editions of Clinics in Liver Disease. He has an active clinical research program for patients with many different chronic liver diseases, including chronic viral hepatitis (HBV and HCV), hepatic encephalopathy, primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis.
Consultant: AbbVie, Gilead, Intercept Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, and Salix Pharmaceuticals.
David Eric Bernstein, MD, PC, is an internationally known gastroenterologist and hepatologist. Currently, he is the president of JSDB Medical Consulting, LLC, and David Bernstein, MD, PC. Dr. Bernstein graduated from the SUNY-Stony Brook School of Medicine. He completed his medical residency at Montefiore Medical Center and completed his fellowship in gastroenterology and hepatology at the University of Miami Affiliated Hospitals under the direction of Dr. Eugene Schiff. He has served as Chief of Gastroenterology at Winthrop Hospital and Chief of Gastroenterology at Long Island Jewish Hospital and North Shore University Hospital. Most recently, he served as the head of the Liver Sub-Specialty Service Line, Vice Chair of Clinical Trials, Chief of the Division of Hepatology, and Director of the Sandra Atlas Bass Center for Liver Diseases for the Northwell Health System. He has also served as a professor of medicine and educational science at the Zucker School of Medicine at Hofstra/Northwell.
Dr. Bernstein's research interests lie primarily in the management and treatment of liver diseases, with most of his work concentrating on developing new treatments for viral hepatitis, primary biliary cholangitis, and fatty liver disease. He has also worked to develop new agents for procedural sedation. Dr. Bernstein has authored or coauthored more than 300 original scientific manuscripts, reviews, book chapters, and abstracts. He has been the principal investigator in more than 200 clinical trials. He is a sought-after lecturer who has frequently been invited to speak at venues across the United States and around the world.
Dr. Bernstein has been involved in shaping public policy and education regarding liver diseases in New York State. He served as a special consultant to the New York State Department of Health. In that role, he helped develop and implement New York State's five-year Strategic Plan for Viral Hepatitis and worked with the group developing the guidelines used for the treatment of hepatitis C in New York State. He regularly leads telemedicine conferences for public health providers, prison health providers, and federally qualified health care centers and has made himself available to these centers, as a special consultant for individual case questions. Dr. Bernstein is well known for his leadership skills and is an expert in such areas as medical program development, health care integration, medical education and curriculum development, clinical care, clinical research, drug development and clinical trials, and team development. Dr. Bernstein is a consultant/advisor to numerous pharmaceutical companies, bio-technology firms, public relations and marketing firms, state governments, and the financial and legal sectors.
Among his many activities, Dr. Bernstein served two terms as an ACG governor for Long Island, is the co-director of the ACG Hepatology School and the ACG Hepatology Circle, and has served on numerous ACG committees over the past 25 years. He was named the American Liver Foundation Physician of the Year in 2016 and has been honored by the Crohn's and Colitis Foundation of New York, the Nassau County Holocaust Memorial Center, the American Cancer Society, and North Shore University Hospital. In 2015, he was the recipient of the SUNY-Stony Brook School of Medicine Distinguished Alumni Award.
He is the author of the column "Liver Lines," which has been published monthly in the Anton Community Newspaper for the past 25 years. He is also a community leader and well-known philanthropist who supports numerous local causes.
David is married to Helen Kim, and they have two children, Sara and Jordan.
Consultant: Mallinckrodt Pharmaceuticals, OcelotBio
Speaker: Intercept Pharmaceuticals
Professor Kevin Moore is one of London's leading and most reputable liver specialists. He is currently a Professor of Hepatology at University College London and sees and treats all forms of liver disease at the Royal Free London Foundation Trust. His main areas of expertise include fatty liver, haemochromatosis, alcoholic liver disease, alcoholism, ascites, and cirrhosis.
Impressively, for twenty years, he was an integral part of the liver transplant team at Royal Free London Foundation Trust, which leads the treatment of cirrhosis complications. Professor Moore sees patients with a wide variety of liver problems, from abnormal liver function tests to advanced cirrhosis. He currently leads the Alcohol Care Team at the Royal Free London NHS Foundation Trust and treats patients with alcohol dependency and alcohol-related liver problems, as well as fatty liver disease, autoimmune liver disease, and cirrhosis.
Professor Moore chaired the writing of the National Plan for Liver Services in 2010, has published two books in acute medicine (Oxford Handbook of Acute Medicine and the Oxford Desk Reference), and has been widely published in numerous peer-reviewed journals.
Consultant: Mallinckrodt Pharmaceuticals